Design Therapeutics, Inc. (DSGN) stock
DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.84−0.08 (-0.81%)
Close on Nov 17, 2026Market cap $615.80MP/E –Yield –
Design Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Design Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$55.08M. For fiscal 2025 it was -$54.36M. The highest annual figure on record is -$8.67M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$54.36M | – |
| FY2024 | Dec 31, 2024 | -$43.11M | – |
| FY2023 | Dec 31, 2023 | -$58.56M | – |
| FY2022 | Dec 31, 2022 | -$51.32M | – |
| FY2021 | Dec 31, 2021 | -$29.38M | – |
| FY2020 | Dec 31, 2020 | -$8.67M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.09M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.50M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.23M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.29M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.66M | – |
See a number that looks wrong?